EA201690284A1 - Композиции и терапевтические способы для ускоренного регресса бляшки - Google Patents

Композиции и терапевтические способы для ускоренного регресса бляшки

Info

Publication number
EA201690284A1
EA201690284A1 EA201690284A EA201690284A EA201690284A1 EA 201690284 A1 EA201690284 A1 EA 201690284A1 EA 201690284 A EA201690284 A EA 201690284A EA 201690284 A EA201690284 A EA 201690284A EA 201690284 A1 EA201690284 A1 EA 201690284A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
acceptable salt
compositions
plair
accelerated
Prior art date
Application number
EA201690284A
Other languages
English (en)
Inventor
Кеннет Юджин Лебиода
Ян Ове Йоханссон
Ф. Аллан Гордон
Фабрицио Симон Кьяккья
Кристофер Росс Армстронг Халлидей
Эвелина Б. Куликовски
Original Assignee
Ресверлоджикс Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ресверлоджикс Корп. filed Critical Ресверлоджикс Корп.
Publication of EA201690284A1 publication Critical patent/EA201690284A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение включает способы лечения и/или предупреждения сердечно-сосудистых, связанных с холестерином и липидами расстройств, в том числе атеросклероза, путем совместного введения терапевтически эффективных количеств RVX-208 или его фармацевтически приемлемой соли и розувастатина или его фармацевтически приемлемой соли. Кроме того, в изобретении предлагаются композиции, содержащие терапевтически эффективное количество RVX-208 или его фармацевтически приемлемой соли и терапевтически эффективное количество розувастатина или его фармацевтически приемлемой соли.
EA201690284A 2013-08-21 2014-08-21 Композиции и терапевтические способы для ускоренного регресса бляшки EA201690284A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361868386P 2013-08-21 2013-08-21
PCT/IB2014/002546 WO2015025226A2 (en) 2013-08-21 2014-08-21 Compositions and therapeutic methods for accelerated plaque regression

Publications (1)

Publication Number Publication Date
EA201690284A1 true EA201690284A1 (ru) 2016-08-31

Family

ID=52484226

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690284A EA201690284A1 (ru) 2013-08-21 2014-08-21 Композиции и терапевтические способы для ускоренного регресса бляшки

Country Status (14)

Country Link
US (1) US20160206617A1 (ru)
EP (1) EP3035934A4 (ru)
JP (1) JP2016528275A (ru)
KR (1) KR20160043117A (ru)
CN (1) CN105473144A (ru)
AU (1) AU2014310369A1 (ru)
BR (1) BR112016003584A8 (ru)
CA (1) CA2921985A1 (ru)
CL (1) CL2016000379A1 (ru)
EA (1) EA201690284A1 (ru)
HK (1) HK1219434A1 (ru)
IL (1) IL244166A0 (ru)
MX (1) MX2016002302A (ru)
WO (1) WO2015025226A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR102215167B1 (ko) 2009-04-22 2021-02-16 리스버로직스 코퍼레이션 신규한 소염제
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
CA2921669A1 (en) * 2013-08-21 2015-02-26 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
BR112022008223A2 (pt) * 2019-11-05 2022-09-06 Resverlogix Corp Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2
EP4087575A4 (en) * 2020-01-08 2024-02-28 Resverlogix Corp METHOD FOR THE TREATMENT AND/OR PREVENTION OF MAJOR CARDIOVASCULAR EVENTS (MACE) USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A DIPEPTIDYLPEPTIDASE-4 INHIBITOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556545A (en) * 2002-03-22 2009-03-31 Novartis Ag Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
WO2008092231A1 (en) * 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
CA2827585A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
WO2014110090A1 (en) * 2013-01-08 2014-07-17 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
CA2921669A1 (en) * 2013-08-21 2015-02-26 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression

Also Published As

Publication number Publication date
BR112016003584A8 (pt) 2018-01-30
WO2015025226A2 (en) 2015-02-26
JP2016528275A (ja) 2016-09-15
WO2015025226A9 (en) 2015-12-03
MX2016002302A (es) 2016-06-15
CL2016000379A1 (es) 2016-08-26
EP3035934A2 (en) 2016-06-29
KR20160043117A (ko) 2016-04-20
AU2014310369A2 (en) 2016-04-21
EP3035934A4 (en) 2017-04-26
CN105473144A (zh) 2016-04-06
US20160206617A1 (en) 2016-07-21
WO2015025226A3 (en) 2015-06-25
AU2014310369A1 (en) 2016-03-10
IL244166A0 (en) 2016-04-21
CA2921985A1 (en) 2015-02-26
HK1219434A1 (zh) 2017-04-07

Similar Documents

Publication Publication Date Title
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
EA201690283A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2021009673A (es) Moduladores de ror-gamma.
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201690962A1 (ru) Составы
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
MX2015017964A (es) Inhibidores de bromodominio.
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
TR201901886T4 (tr) DNA-PK inhibitörleri.
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
IN2014DN10670A (ru)
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.